+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Aggrenox

  • ID: 4775301
  • Report
  • July 2018
  • Region: Global
  • 13 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole. Each active ingredient inhibits platelet aggregation through a distinct pathway. Aspirin works by irreversibly inhibiting the cyclooxygenase-1 and cyclooxygenase-2 enzymes, which are responsible for the synthesis of prostaglandins and thromboxanes.

Prostaglandins and thromboxanes trigger the platelet aggregation needed for clot formation to occur. By inhibiting cyclooxygenase-1 and cyclooxygenase-2, Aspirin decreases the number of prostaglandins and thromboxanes present, resulting in a reduction in platelet aggregation. By limiting platelet aggregation, Aspirin inhibits blood clot formation.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Aggrenox: Stroke

LIST OF FIGURES
Figure 1: Aggrenox for ischemic stroke – SWOT analysis
Figure 2: The authors drug assessment summary of Aggrenox for ischemic stroke
Figure 3: The authors drug assessment summary of Aggrenox for ischemic stroke

LIST OF TABLES
Table 1: Aggrenox drug profile
Table 2: Aggrenox pivotal trial data in ischemic stroke
Table 3: Aggrenox late-phase trial data in ischemic stroke
Note: Product cover images may vary from those shown
Adroll
adroll